Gland Pharma share news, announcements and annual reports
NSE: GLANDBSE: 543245Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,074.50.
30 Oct: open ₹3,070.00, high ₹3,114.20, low ₹3,051.00
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹51,086 Cr261st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 45.26
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.65%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,00,302
Gland Pharma share news and announcements
549 announcements, routine notices left out, newest first. Page 10 of 11.
Oct 2021
26 Oct · Analysts
26 Oct · Analysts
25 Oct · Business
22 Oct · Results
22 Oct · Board meeting
7 Oct · Disclosure
5 Oct · Analysts
Sep 2021
27 Sep · Analysts
24 Sep · Analysts
23 Sep · Analysts
21 Sep · Analysts
21 Sep · Analysts
16 Sep · Analysts
11 Sep · Analysts
6 Sep · Analysts
3 Sep · Analysts
Aug 2021
30 Aug · Analysts
27 Aug · Meeting
16 Aug · Analysts
9 Aug · Analysts
Jul 2021
31 Jul · Analysts
29 Jul · Analysts
28 Jul · Analysts
26 Jul · Analysts
21 Jul · Business
21 Jul · Results
21 Jul · Board meeting
5 Jul · Disclosure
5 Jul · Analysts
Jun 2021
28 Jun · Board meeting
28 Jun · Analysts
28 Jun · Analysts
22 Jun · Analysts
19 Jun · Analysts
11 Jun · Analysts
7 Jun · Analysts
May 2021
31 May · Legal
Exchange has sought clarification from Gland Pharma Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.29 May · Analysts
29 May · Analysts
25 May · Analysts
24 May · Analysts